VolitionRx Completes $9 Million Private Placement Offering

Represented VolitionRx Limited (NYSE American: VNRX) in connection with its $9 million private placement of public equity (PIPE) offering, consisting of 5 million shares of the company’s common stock at a price of $1.80 per share and a warrant to purchase up to an additional 5 million shares of common stock at a price of $3.00 per share. VolitionRx intends to use the net proceeds from the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes. Read the press release.

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

The Newport Beach-based deal team representing VolitionRx included Marc Alcser and Matthew Brodsky.

Please enable JavaScript, then refresh this page. JavaScript is required on this site.